Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Sunitinib in the Treatment of Recurrent Malignant Gliomas

NCT00923117 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00923117
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00923117 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Sunitinib in the Treatment of Recurrent Malignant Gliomas
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Terminated
Start date
June 30, 2008
Completion date
June 30, 2012
Enrollment
87 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic gliomas, glioblastoma multiforme, malignant gliomas